A Phase 3 interventional study of Ibuprofen and Aprepitant in Primary Dysmenorrhea, sponsored by Lahore Medical Research Center, LLP. Completed at 1 site in Pakistan. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-21.
Sponsored by Lahore Medical Research Center, LLP · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Dysmenorrhea with a site in Pakistan — 9 open to participants now, 11 under way, none of them phase 3. Dysmenorrhea · Pakistan.
Among the 28 studies in Dysmenorrhea with a site in Pakistan, this one is the 14th largest by enrollment, is one of 4 that started in 2024, is the only one in phase 3, and was the 13th registered.
432 studies on the registry are indexed under Dysmenorrhea; 109 are open to participants now.
Browse Dysmenorrhea studies →9 of the 28 studies in Dysmenorrhea with a site in Pakistan are open now. Recruiting first, the newest first:
Riphah International University · Sites in Pakistan
Ages 18–24 · Women only
Dr. Mehak Naeem · Sites in Pakistan
Ages 18–30 · Women only
University of Hail · Sites in Pakistan
Ages 18–30 · Women only
Riphah International University · Sites in Pakistan
Ages 13–19 · Women only · Healthy volunteers
Riphah International University · Sites in Pakistan
Ages 17–24 · Women only
A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →
Of the 59 Dysmenorrhea studies recruiting now, 7 (12%) set no upper age limit and 51 (86%) stop at 75 or younger; 11 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 62 across 364 interventional studies indexed under Dysmenorrhea.
Median enrollment 40 across the 28 interventional studies. Of the 14 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 28 have an industry lead sponsor. The 9 most frequent:
This is the only study on the registry with Lahore Medical Research Center, LLP as lead sponsor.
Lahore Medical Research Center, LLP has 1 study filed under Dysmenorrhea — fewer than ten, so there is no comparison to draw.
1 of the studies in Dysmenorrhea with a site in Pakistan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07754305Riphah International UniversityDiaphragm-Pelvic Floor Synergy Training in Young Females With Primary Dysmenorrhea. | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 28 studies in Dysmenorrhea with a site in Pakistan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Dysmenorrhea is characterized as excruciating menstrual cramps of uterine origin and is one of the most prevalent gynecological illnesses. Substance P (SP) and NK1R mediate the symptoms of various pain disorders with chronic and/or neuropathic pain. Objective: To evaluate diagnostic and therapeutic potential of Substance P/ NK1R receptor in primary dysmenorrhea. Study Design: This was a randomized controlled trial which took place at Lahore Medical Research Center from March 2024 to October 2024. Non-probability convenient sampling techniques was used for sampling. A total of 40 female participants was included in the study who met specific criteria for inclusion. The study comprised of three phases, Phase 1 (Before medication), Phase 2 (NSAIDs) and Phase 3(Dexamethasone + Aprepitant). 10 females with no dysmenorrhea participated as controls. The study duration spanned three menstrual cycles. 20 dysmenhorric and 6 controls were analyzed for NK1R levels. Several assessment tools were also used in the study,
This was a randomized controlled trial which took place at Lahore Medical Research Center from March 2024 to October 2024. Non-probability convenient sampling techniques was used for sampling. A total of 40 female participants was included in the study who met specific criteria for inclusion. 10 females with no dysmenorrhea participated as controls. The study duration spanned three menstrual cycles, during which participants were divided into three Phases. Phase 1: Blood samples of all 30 patients were collected prior to any medication. Phase 2: All 30 participants in this phase used NSAIDs (Non-steroidal Anti-Inflammatory Drugs), during their dysmenorrhea period. Phase 3: All the patients from phase 2 (n=30) received NK1R antagonist "Dexamethasone (6mg) + Aprepitant (80mg)" for 2 days. Out of these patients, 20 dysmenhorric and 6 controls were analyzed for NK1R levels.
Data Collection
A 5cc blood sample was collected from each participant on the 2nd day of their menstrual cycle before any intervention. Another 5cc blood sample was collected on the 2nd day of the menstrual cycle after the first intervention. Another 5cc blood sample was collected on the 2nd day of the menstrual cycle after the 2nd intervention. Prior to and following the intervention, a complete blood count (CBC) was conducted to assess any changes in blood parameters. Serum was extracted from the collected blood samples for further analysis.
Human SP and Neurokinin-1 Receptor (NK1R) levels measurement Human SP and its antagonist NK1R levels were analyzed using ELISA technique. This analysis was performed thrice to investigate the role of Substance P and NK1R in menstrual pain before and after the intervention. BT Lab Human Substance P and NK1R ELISA kit was used to measure levels of SP and NK1R in serum samples of participants (Catalogue Numbers: E1528Hu, E6938Hu).
Assessment tools
The study's participants filled out a basic questionnaire meant to collect sociodemographic information and analyze a variety of parameters. Body Mass Index (BMI), Family History of Pain, Age at Menarche, Length of Menstrual Cycle, Age of Onset of Dysmenorrhea, and Sleep Duration were all included in these surveys. The Depression Anxiety Stress Scale (DASS), Visual Analogue Scale (VAS), Mini Nutritional Assessment (MNA), International Physical Activity Questionnaire (IPAQ), and Pictorial Blood Loss Assessment Chart were among the other questionnaires used.
Visual Analogue Scale (VAS)
Female participants' levels of pain were measured using the Visual Analog Scale (VAS). With a scale from 0 to 10, where 10 is the most excruciating pain possible, the VAS is a well-known measure for assessing pain perception. Participants were divided into three groups to reflect varied levels of pain severity based on their VAS ratings obtained throughout the first three consecutive days of both menstrual cycles: Mild Pain, Moderate Pain, and Severe Pain.
Mini Nutritional Assessment (MNA)
The female participants' eating patterns were assessed using the Nestle Nutrition Institute Mini Nutritional Assessment in order to look into any possible associations between their diet and menstrual discomfort. Participants who scored between 24 and 30 had good nutritional status, those who scored from 17 to 23.5 were at risk of malnutrition, and those who scored under 17 were poorly nourished.
Depression Anxiety Stress Scale (DASS-21)
The DASS-21 was used to evaluate the psychological health of our subjects and comprehend how it related to dysmenorrhea. Based on their stated levels of stress, anxiety, and depression, participants were divided into five groups using this scale: normal, mild, moderate, severe, and extremely severe. A score of 0 to 9 indicates normal, 10 to 13 indicates mild depression, 14 to 20 indicates moderate depression, 21 to 27 indicates severe depression, and 28 or above indicates extremely severe depression. Scores between 0 and 7 indicate normal anxiety, 8 to 9 indicate mild anxiety, 10 to 14 indicate moderate anxiety, 15 to 19 indicate severe anxiety, and 20 or more indicate extremely severe anxiety. For stress, 0-14 represents normal, 15-18 represents mild, 19-25 represents moderate, 26-33 represents severe, and 34+ represents really severe stress.
Pictorial Blood Loss Assessment Chart (PBAC)
The Pictorial Blood Loss Assessment Chart (PBAC), a self-administered pictorial assessment chart that assigns scores based on how much tampons and cotton-based sanitary pads stain throughout a menstrual cycle, was given to the patients as a tool to measure their menstrual blood volume [24-26]. Reliability of the PBAC has been shown [25, 26]. They were given guidelines by the researcher on how to utilize the PBAC. Hypomenorrhea was linked to PBAC scores of 10 or less, regular monthly flow was linked to PBAC scores of 10 to 99, and heavy menstrual bleeding was linked to PBAC scores of 100 or more for two months. Cotton pads were the only sanitary goods used. Software for statistical analysis was used to determine scores.
Statistical Analysis
Data analysis was carried out using Graph Pad Prism 8.0.2, a statistical software package. The collected data, including questionnaire responses, CBC results, Substance P and NK1R levels, were analyzed to assess the effects of the interventions on menstrual pain and related factors. Two-way ANOVA test was used for analysis. P-value less than 0.05 was considered significant.
Ethical considerations
This study was approved by Ethical Review Board of Lahore Medical Research Center. The research followed declaration of Helsinki and written and informed consent was taken from all participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The participants must be unmarried women of reproductive age who have moderate to severe dysmenorrhea.
Exclusion Criteria:
Those with irregular or infrequent menstrual cycles.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10 females with no dysmenorrhea participated as controls.
All 30 participants in this group used NSAIDs (Non-steroidal Anti-Inflammatory Drugs), during their dysmenorrhea period. Same patients from phase 2 (n=30) in next cycle received NK1R antagonist "Dexamethasone (6mg) + Aprepitant (80mg)" for 2 days.
Drug: Ibuprofen and Aprepitant
Drug pages: Ibuprofen · Aprepitant
All 30 participants in this group used NSAIDs (Non-steroidal Anti-Inflammatory Drugs), during their dysmenorrhea period. Same patients from phase 2 (n=30) in next cycle received NK1R antagonist "Dexamethasone (6mg) + Aprepitant (80mg)" for 2 days.
Also known as: NSAIDs, Neurokinin 1 Receptor antagonist
Visual Analogue Scale Score (Pain scale)
Female participants' levels of pain were measured using the Visual Analog Scale (VAS). With a scale from 0 to 10, where 10 is the most excruciating pain possible, the VAS is a well-known measure for assessing pain perception. Participants were divided into three groups to reflect varied levels of pain severity based on their VAS ratings obtained throughout the first three consecutive days of both menstrual cycles: Mild Pain, Moderate Pain, and Severe Pain
Time frame: At the end of one cycle (each cycle is of 28-3- days)
Mini Nutritional Assessment (MNA) Score
The female participants' eating patterns were assessed using the Nestle Nutrition Institute Mini Nutritional Assessment in order to look into any possible associations between their diet and menstrual discomfort. Participants who scored between 24 and 30 had good nutritional status, those who scored from 17 to 23.5 were at risk of malnutrition, and those who scored under 17 were poorly nourished.
Time frame: At the end of one cycle (each cycle is of 28-3- days)
DASS-21 (Depression Anxiety Stress Scale)
The DASS-21 was used to evaluate the psychological health of our subjects and comprehend how it related to dysmenorrhea. Based on their stated levels of stress, anxiety, and depression, participants were divided into five groups using this scale: normal, mild, moderate, severe, and extremely severe. A score of 0 to 9 indicates normal, 10 to 13 indicates mild depression, 14 to 20 indicates moderate depression, 21 to 27 indicates severe depression, and 28 or above indicates extremely severe depression. Scores between 0 and 7 indicate normal anxiety, 8 to 9 indicate mild anxiety, 10 to 14 indicate moderate anxiety, 15 to 19 indicate severe anxiety, and 20 or more indicate extremely severe anxiety. For stress, 0-14 represents normal, 15-18 represents mild, 19-25 represents moderate, 26-33 represents severe, and 34+ represents really severe stress.
Time frame: At the end of one cycle (each cycle is of 28-3- days)
Pictorial Blood Loss Assessment Chart (PBAC)
The Pictorial Blood Loss Assessment Chart (PBAC), a self-administered pictorial assessment chart that assigns scores based on how much tampons and cotton-based sanitary pads stain throughout a menstrual cycle, was given to the patients as a tool to measure their menstrual blood volume. Reliability of the PBAC has been shown. They were given guidelines by the researcher on how to utilize the PBAC. Hypomenorrhea was linked to PBAC scores of 10 or less, regular monthly flow was linked to PBAC scores of 10 to 99, and heavy menstrual bleeding was linked to PBAC scores of 100 or more for two months. Cotton pads were the only sanitary goods used. Software for statistical analysis was used to determine scores.
Time frame: At the end of one cycle (each cycle is of 28-3- days)
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2024 to primary completion in Oct 2024, 7 months.
Of 17 phase 3 interventional studies under Dysmenorrhea, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 30. This study's 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ibuprofen · Aprepitant